Ignite Creation Date:
2024-05-05 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00282087
Status:
COMPLETED
Last Update Posted:
2014-12-01
First Post:
2006-01-24
Brief Title:
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Sponsor:
Sarcoma Alliance for Research through Collaboration
Organization:
Sarcoma Alliance for Research through Collaboration
Study Overview
Official Title:
Adjuvant Treatment of High Risk Uterine Leiomyosarcoma With GemcitabineDocetaxel Followed by Doxorubicin A Phase II Trial
Status:
COMPLETED
Status Verified Date:
2014-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to study the benefits of giving chemotherapy to women after they have had surgical resection of their primary disease and have no evidence of disease remainingknown as adjuvant therapy The major objective of this study is to determine the progression free survival The goal is to prevent relapse or recurrence of their uterine leiomyosarcoma
Detailed Description:
Patients with a diagnosis of early-stage uterine leiomyosarcoma have a 70 chance of relapse or recurrence of their disease Patients enrolled in this trial will receive 4 cycles of gemcitabine and docetaxel followed by 4 cycles of adriamycin Following completion of chemotherapy they will be have repeat imaging at regular intervals to monitor for disease recurrence along with periodic clinical evaluations
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MSKCC05-128 | OTHER | Memorial Sloan-Kettering Cancer Center | None |